Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorGuangzhou Burning Rock Dx Co., Ltd.
About this trial
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
Eligibility criteria
Qualifiers
Participants must be able to provide a written informed consent form
Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form
Participants must be able to provide blood samples for study tests
Participants must be between 40 and 75 years old
Disqualifiers
Individuals who have an acute infection or inflammation within 14 days prior to recruitment
Individuals with cancer-associated clinical symptoms or suspected of cancer
Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
Recipient of blood transfusion within 7 days prior to recruitment
Trial design
Treatments tested in this trial
- OverC multi-cancer detection blood test
Treatment groups
12,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Guangzhou Burning Rock Dx Co., Ltd.
Lead sponsor
West China Hospital
Collaborator
Source ClinicalTrials.gov